Navigation Links
FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue. The HER2 gene is located on chromosome 17 in human cells. An excessive amount of the protein produced by the gene is found in some types of cancer cells, including breast cancer cells.

The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. The sample is stained with chemicals that cause copies of HER2 genes and chromosome 17 to change color. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. These color changes can be seen under a standard microscope.

This feature allows lab personnel to see and count copies of chromosome 17 and HER2 genes on the same slide, similar to HER2 amplification measurements that have traditionally only been available using fluorescence microscopes. The Inform Dual ISH, however, allows lab staff to see the HER2 and chromosome 17 signals directly under a microscope, for longer periods of time.

"When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health.

The FDA based its approval of the Inform Dual ISH on a U.S. study involving tumor
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... Ohio Heart patients with beliefs about health that ... skip sessions of cardiac rehabilitation, new research suggests. , ... of these beliefs referred to as "irrational health ... was associated with lower adherence to a prescribed cardiac ... Doubting the preventive power of the flu vaccine or ...
(Date:4/14/2014)... high-risk bladder cancer, chemotherapy before or after surgery ... The findings are published early online in ... Cancer Society. , Clinical trials have shown that ... cancer who are given chemotherapy before surgery. There ... also improves survival. To investigate the use of ...
Breaking Medicine News(10 mins):Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... Ontario (CHEO )researcher has found that children and babies are ... fact that generation subsists on cod liver oil, ... has persisted in too many children in Canada. ... stunts growth, the disease can cause painful bone deformities. Very ...
... has shown that regular vaccination of infants against H. ... Hib pneumonia and meningitis, could save innumerable children in ... is published online in The Pediatric Infectious Disease Journal, ... Hib conjugate vaccine prevented more than one-third of acute ...
... focused on cognitive skills may improve child behaviour. ... of the New York Academy of Sciences children who ... consideration of their own and others' emotions were found ... emotional problems. ,The study showed that ...
... to afflict humans very early, not sparing even tiny tots. Children ... in New South Wales in Australia. ,Anxiety disorders ... Macquarie University's Anxiety Research Unit show. ,In children aged ... compared to a rate of about 1 per cent for mood ...
... one bacterial species into another by swapping their genomes, a ... bugs, a pioneer on genetics said Thursday. ... genome, said a team of his researchers had transplanted the ... related species. ,The experiment marks the most ambitious ...
... in movie 'Hairspray', is happy the female costumes he wore helped ... having to wear a fat suit, dress, and high heels to ... iconic musical-turned-movie was the perfect combination to shed the pounds. ... of weight to carry around," Contactmusic quotes him as saying. ...
Cached Medicine News:Health News:Vitamin D Deficiency Still Persists in Babies 2Health News:Routine Hib Vaccination Could Save Innumerable Asian Children 2Health News:Routine Hib Vaccination Could Save Innumerable Asian Children 3Health News:Cognitive Skills Focused Curriculum may Lessen Kids' Behavioural Problems 2Health News:Anxiety Disorders Show in Tiny Tots 2Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 2Health News:Replacing a Genome Boosts Race to Develop Designer Bugs: Study 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: